Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 244,061 | 3,550 | 151 | 0 | 20,100 |
| Gross Profit | 244,061 | 3,550 | 151 | N/A | 20,100 |
| Operating Expenses | 176,492 | 214,383 | 170,092 | 114,790 | 76,473 |
| Operating Income | 67,569 | -210,833 | -169,941 | -114,790 | -56,373 |
| Interest Expense | 0 | 0 | 0 | 1 | 4 |
| Other Income | 24,328 | 23,780 | 16,949 | 10,112 | -356 |
| Pre-tax Income | 91,897 | -187,053 | -152,992 | -104,679 | -56,733 |
| Income Tax | 4,883 | 300 | N/A | N/A | 2,011 |
| Net Income Continuous | 87,014 | -187,353 | -152,992 | -104,679 | -58,744 |
| Net Income | $87,014 | $-187,353 | $-152,992 | $-104,679 | $-58,744 |
| EPS Basic Total Ops | 2.34 | -5.00 | -5.20 | -4.15 | -2.52 |
| EPS Basic Continuous Ops | 2.34 | -5.00 | -5.20 | -4.15 | -2.52 |
| EPS Diluted Total Ops | 2.30 | -5.00 | -5.20 | -4.15 | -2.52 |
| EPS Diluted Continuous Ops | 2.30 | -5.00 | -5.20 | -4.15 | -2.52 |
| EPS Diluted Before Non-Recurring Items | 2.30 | -5.00 | -5.20 | -4.15 | -2.52 |
| EBITDA(a) | $69,078 | $-209,604 | $-169,126 | $-114,116 | $-55,995 |